J Matt McCrary1, David Goldstein2, Terry Trinh1, Hannah C Timmins3, Tiffany Li3, Michael Friedlander2, Annmarie Bosco4, Michelle Harrison5, Natalie Maier6, Siobhan O'Neill7, Susanna B Park8. 1. Prince of Wales Clinical School, University of New South Wales, Kensington, Australia. 2. Prince of Wales Clinical School, University of New South Wales, Kensington, Australia; Prince of Wales Hospital, Randwick, Australia. 3. Brain and Mind Centre, The University of Sydney, Camperdown, Australia. 4. Prince of Wales Hospital, Randwick, Australia; School of Medical Science, University of New South Wales, Kensington, Australia. 5. Royal Prince Alfred Hospital, Camperdown, Australia; The Chris O'Brien Lifehouse, Camperdown, Australia. 6. Sydney Hospital and Sydney Eye Hospital, Sydney, Australia. 7. Prince of Wales Hospital, Randwick, Australia. 8. Prince of Wales Clinical School, University of New South Wales, Kensington, Australia; Brain and Mind Centre, The University of Sydney, Camperdown, Australia. Electronic address: susanna.park@sydney.edu.au.
Abstract
CONTEXT: Efficient and accurate clinical screening for treatment-related toxicities is a critical component of optimal patient management. A number of alternate screening tools for chemotherapy-induced peripheral neuropathy (CIPN) have been proposed in response to demonstrated limitations with standard clinical screening, although their relative diagnostic value is unclear. OBJECTIVES: The aim of this study is to evaluate the relative construct validity and discriminant properties of available CIPN screening tools. METHODS: Patients treated with known potentially neurotoxic therapies underwent CIPN evaluation at one or multiple timepoints (N = 316 patients; age = 56 ± 13 years). At each testing session (N = 644 testing sessions), patients were evaluated using screening tools and comprehensive CIPN assessments. Comprehensive assessments were clinician-rated (Total Neuropathy Score, reduced) or patient-reported outcome (PRO; Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity questionnaire). Similarly, screening tools were clinician-rated (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE]) or PRO (Patient Neurotoxicity Questionnaire, PRO-CTCAE). RESULTS: Analyses revealed moderate-to-high correlations between screening tools and comprehensive assessments (0.55 ≤ rho ≤ 0.75; P < 0.001) and similar discriminant properties across screening tools (P > 0.01). Screening tool grading corresponding to clinically significant (grade 2/3) vs. low-grade (grade 0/1) CIPN would correspond to greater ratings of CIPN severity by more comprehensive assessments in a predicted 77%-91% of cases (c-statistic = 0.77-0.91; P < 0.01). CONCLUSIONS: PRO screening tools provide adequate CIPN screening while avoiding potential biases demonstrated to limit currently used clinician-rated screening tools. Addition of a brief objective test did not add value to PRO screening. Up to 23% of patients would be misidentified through screening, providing quantitative evidence of the limitations of available screening tools. More extensive CIPN evaluations are critical in patients at risk of serious neurotoxicity.
CONTEXT: Efficient and accurate clinical screening for treatment-related toxicities is a critical component of optimal patient management. A number of alternate screening tools for chemotherapy-induced peripheral neuropathy (CIPN) have been proposed in response to demonstrated limitations with standard clinical screening, although their relative diagnostic value is unclear. OBJECTIVES: The aim of this study is to evaluate the relative construct validity and discriminant properties of available CIPN screening tools. METHODS:Patients treated with known potentially neurotoxic therapies underwent CIPN evaluation at one or multiple timepoints (N = 316 patients; age = 56 ± 13 years). At each testing session (N = 644 testing sessions), patients were evaluated using screening tools and comprehensive CIPN assessments. Comprehensive assessments were clinician-rated (Total Neuropathy Score, reduced) or patient-reported outcome (PRO; Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity questionnaire). Similarly, screening tools were clinician-rated (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE]) or PRO (PatientNeurotoxicity Questionnaire, PRO-CTCAE). RESULTS: Analyses revealed moderate-to-high correlations between screening tools and comprehensive assessments (0.55 ≤ rho ≤ 0.75; P < 0.001) and similar discriminant properties across screening tools (P > 0.01). Screening tool grading corresponding to clinically significant (grade 2/3) vs. low-grade (grade 0/1) CIPN would correspond to greater ratings of CIPN severity by more comprehensive assessments in a predicted 77%-91% of cases (c-statistic = 0.77-0.91; P < 0.01). CONCLUSIONS: PRO screening tools provide adequate CIPN screening while avoiding potential biases demonstrated to limit currently used clinician-rated screening tools. Addition of a brief objective test did not add value to PRO screening. Up to 23% of patients would be misidentified through screening, providing quantitative evidence of the limitations of available screening tools. More extensive CIPN evaluations are critical in patients at risk of serious neurotoxicity.
Authors: Deborah J Bowen; Eileen H Shinn; Sophie Gregrowski; Gretchen Kimmick; Laura S Dominici; Elizabeth S Frank; Karen Lisa Smith; Gabrielle Rocque; Kathryn J Ruddy; Teri Pollastro; Michelle Melisko; Tarah J Ballinger; Oluwadamilola M Fayanju; Antonio C Wolff Journal: Cancer Date: 2019-11-19 Impact factor: 6.860
Authors: Larissa Nekhlyudov; Grace B Campbell; Kathryn H Schmitz; Gabriel A Brooks; Anita J Kumar; Patricia A Ganz; Diane Von Ah Journal: Cancer Date: 2021-09-16 Impact factor: 6.921
Authors: Tiffany Li; Susanna B Park; Eva Battaglini; Madeleine T King; Matthew C Kiernan; David Goldstein; Claudia Rutherford Journal: Qual Life Res Date: 2022-05-21 Impact factor: 3.440